	US 12,465,589 B2
	Method and composition for treating CNS disorders
Ramachandra Mukunda, Potomac, MD (US); Jagadeesh S. Rao, Ashburn, VA (US); and Amar R. Mukunda, Bethesda, MD (US)
Assigned to IGC Pharma IP, LLC, Potomac, MD (US)
Filed by IGC Pharma IP, LLC, Potomac, MD (US)
Filed on Apr. 14, 2023, as Appl. No. 18/301,099.
Application 18/301,099 is a division of application No. 17/042,333, abandoned, previously published as PCT/US2019/000014, filed on Mar. 29, 2019.
Claims priority of provisional application 62/650,942, filed on Mar. 30, 2018.
Prior Publication US 2023/0248697 A1, Aug. 10, 2023
Int. Cl. A61K 31/4045 (2006.01); A61K 9/107 (2006.01); A61K 31/00 (2006.01); A61K 31/12 (2006.01); A61K 31/7048 (2006.01)

CPC A61K 31/4045 (2013.01) [A61K 31/12 (2013.01); A61K 31/658 (2023.05); A61K 31/7048 (2013.01); A61K 9/107 (2013.01)]

13 Claims

1. Composition for treating symptoms of Alzheimer's disease; the composition comprising:

(i) tetrahydrocannabinol (THC) in a dose amount per 70 kg patient from 1.0 mg to 3.0 mg,

(ii) melatonin in a dose amount per 70 kg patient from about 14 μg to about 77.0 mg, and

(iii) curcumin in a dose amount per 70 kg patient from about 0.35 mg up to 0.5 mg.